Threat to Advair from cheap generics greets GSK's new CEO
London
EMMA Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.
Just four days before she moves into the top job on April 1, US regulators could approve the first substitutable generic version of GSK's inhaled lung drug Advair, which has raked in more than a US$1 billion in sales every year since 2001.
Ms Walmsley is expected to formally present her …
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop
Cordlife customers push for legal action
Apparel company Express seeks quick bankruptcy sale